- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 11:46 | Gilead and PAHO agree to expedite lenacapavir access for HIV prevention | ||
| 10:46 | Eli Lilly and QurCan sign genetic medicine deal | ||
| Di | Electra targets $342m IPO to fund hyperinflammatory syndrome drug's pivotal trials | ||
| Di | Agentic AI trust gap slowing healthcare provider adoption, survey reveals | ||
| Di | GSK bolsters oncology pipeline with $750m Chimagen TCE deal | ||
| Di | Definium tees up regulatory submission for psychedelic on Phase III hat trick | ||
| Di | Cheplapharm to take over 20 medicines and three sites from Sanofi | ||
| Di | FDA reduces monitoring time for Amgen's Imdelltra infusions | ||
| Mo | No more Nordisk: Novo's latest trim is in its name | ||
| Mo | Scholar Rock's muscle-targeting SMA therapy Isemblyd lands FDA approval | ||
| Fr | HIV charities lament NICE snub for Gilead's twice-yearly lenacapavir | ||
| Fr | Exegenesis Bio and Modalis sign research deal for Duchenne therapy | ||
| Fr | ABEC to expand global manufacturing network with new Wilson facility | ||
| Do | Encoded secures $275m for Dravet syndrome gene therapy | ||
| Do | Bayer's Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion | ||
| Do | HHS appoints permanent FDA CBER, CDER heads | ||
| Do | Solstice Oncology secures $225m to drive porustobart's development for cancer | ||
| Do | TwoStep Therapeutics secures $62.5m funding to advance TS-104 | ||
| 09.09. | Why China's rise needs to be taken with a pinch of salt | ||
| 09.09. | Pharma's R&D, commercial approach shifts amid global policy evolution | ||
| 09.09. | Moonwalk banks $70m to progress siRNA therapy for obesity | ||
| 09.09. | "Unparalleled opportunity": Sandoz embarks on ambitious biosimilar growth strategy | ||
| 09.09. | Gilead launches research facility in US for new medicine development | ||
| 09.09. | FDA grants RMAT designation to RiboX's RXRG001 for xerostomia | ||
| 09.09. | Quoin in line for priority review voucher if rare paediatric drug approved |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.